AN2 Therapeutics, Inc.
ANTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $41,163 | $483,564 | $146,190 | $288,596 |
| - Cash | $21,351 | $15,647 | $27,219 | $12,097 |
| + Debt | $0 | $0 | $53 | $0 |
| Enterprise Value | $19,812 | $467,917 | $119,024 | $276,499 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | -$77 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $3,233 | $4,903 | -$40,879 | -$21,574 |
| % Margin | – | – | – | – |
| Net Income | -$51,321 | -$64,732 | -$40,956 | -$21,543 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.72 | -2.74 | -2.79 | -1.5 |
| % Growth | 37.2% | 1.8% | -86% | – |
| Operating Cash Flow | -$49,257 | -$53,288 | -$33,462 | -$20,484 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$49,257 | -$53,288 | -$33,462 | -$20,484 |